; (ii) the track record and demonstrated ability of the given manufacturer to produce the designated critical medication in the required quantities when needed (in domestic or foreign locations, after consideration of whether supply from such foreign locations is at significant risk of disruption in the event of a public health emergency); and (iii) the United States regulatory compliance history of the given manufacturer. (C) Preference In entering into contracts under subparagraph (A)(ii), the Secretary may give preference to contracting with manufacturers of medications which are based in the United States. (D) References References in this paragraph to the United States include any territory of the United States. ; (2) in subsection (a)(2)(B)— (A) in the matter preceding clause (i), by inserting and each new or modified contract with a private entity under paragraph (1)(A)(ii) after for each new or modified countermeasure procurement or replenishment ; (B) in clause (i)(III), by inserting or contracting for procurement after procurement ; (C) in clause (i)(IV), by inserting or contracting for procurement after whether such procurement ; (D) in clause (i)(V), by inserting (including through one or more contracts under paragraph (1)(A)(ii)) after stockpile ; and (E) in clause (ii), by inserting or for which the Secretary entered into a contract with a private entity under paragraph (1)(A)(ii), after for each countermeasure procured or replenished under this subsection, ; (3) in subsection (a)(3)(E) by inserting the Commissioner of Food and Drugs, after Assistant Secretary for Preparedness and Response, ; (4) in subsection (a)(5)(A)— (A) in the matter preceding clause (i), by inserting and any contracts entered into under paragraph (1)(A)(ii) after any changes to the contents or management of the stockpile ; (B) in clause (ii), by striking or replenishment and inserting replenishment, or contracting